IRVINE, CA / ACCESS Newswire / October 16, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) is issuing this press release in an effort to help avoid any confusion in the marketplace between the common stock of Pro-Dex, Inc., which trades on the Nasdaq Capital Market under the symbol PDEX, and Polkadex, which to Pro-Dex, Inc.'s understanding trades on certain crypto exchanges (and possibly on certain other platforms) under the same symbol. There is no relationship or affiliation between Pro-Dex, Inc. and Polkadex. Given that both Pro-Dex, Inc. and Polkadex are associated with the PDEX symbol, investors are encouraged to carefully inquire as to any research or trading involving the PDEX symbol to ensure that any such research or trade accurately reflects the investor's intent as between Pro-Dex, Inc. or Polkadex.
About Pro-Dex, Inc.
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also sells rotary air motors, however, these motors represent a de minimis portion of total revenue. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.
Contact:
Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200
| Last Trade: | US$41.50 |
| Daily Change: | -1.18 -2.76 |
| Daily Volume: | 15,829 |
| Market Cap: | US$135.290M |
December 19, 2025 October 30, 2025 September 04, 2025 September 05, 2024 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load